PRA buys out Takeda JV in Japan

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: Pra health sciences, Takeda, Japan

PRA Health Sciences has bought out its joint venture with Takeda, establishing a new subsidiary based in Japan – a rapidly growing market, says EVP.

PRA Health Sciences K.K. is now operating as a PRA subsidiary in Japan following PRA Health Sciences buyout of its joint venture with Takeda Pharmaceutical Company Limited, which was established in 2017.

The addition of Takeda’s staff increases PRA’s totals employee numbers to 450 in Japan, with the opportunity for additional growth in the near term, according to the company.

Including the PRA’s new offices in Tokyo and Osaka, the company currently has more than 2,300 staff members across 15 countries in the Asia region.

“Our vision is to be the premier pharma partner in Japan by expanding our operations and expertise across therapeutic areas and functions to serve Japan and the entire Asia Pacific region,”​ said Samir Shah, executive vice president and president, strategic solutions at PRA Health Sciences.

“Asia is the third largest market for biopharmaceutical outsourcing, and Japan is rapidly growing. PRA has made an investment in the region reflective of the business opportunity,”​ he told us.

As for integration, Dr. Atsushi Ogawa, president and representative director of PRA Japan, said the process is progressing “steadily and smoothly.” ​The company is already conducting in-house work and providing services to clients, including Takeda, he told us.

“PRA Japan provides flexible infrastructure, end-to-end clinical development across all phases, embedded solutions, and technology and data science,”​ Ogawa added.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars